Reduce Sedentary Behavior During Cancer Treatment - the RedSedCan Study

Study acronym: RedSedCan
StatusRecruiting
PhaseNot applicable
Started

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Track this trial
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Enrollment increased: 172 → 210 participants
    • Eligibility criteria expanded, about 6 words
    • Secondary endpoints: details revised at 2 of 10 entries
  2. Trial status: Not Yet Recruiting to Recruitingv2 Show 6 more changesShow less
    • Primary completion date: Jun 1, 2029 to Dec 31, 2029
    • Study sites: 0 to 2
    • Study completion date: Jun 1, 2029 to Dec 31, 2030
    • Start date changed from estimate of Dec 15, 2024 to Mar 1, 2025
    • Collaborators revised (5)
    • Study description expanded, about 2 words
  3. Study First Submitted
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
Summary Reducing sedentary behavior during treatment is important to reduce the risk of future health problems in individuals undergoing cancer treatment. Therefore, the goal of this project is with a multicenter randomised controlled design investigate whether a digital support intervention during ongoing neo- or adjuvant cancer treatment for breast, prostate or colon cancer is effective in reducing sedentary lifestyle and improving well-being in the short and long term.
Trial Details
NCT Number NCT06719206
Lead Sponsor Mälardalen University
Collaborators: Region Västmanland, Uppsala University, Centrallasarettet Västerås, Uppsala University Hospital, Uppsala County Council, Sweden
Conditions
(from sponsor)		 Breast Cancer, Colorectal Cancer (CRC), Prostate Cancer, Neoadjuvant Therapy, Adjuvant Therapy
Related terms Breast Neoplasms, Colorectal Neoplasms, Prostatic Neoplasms, Sedentary Behavior
Enrollment 210 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov